3 stories mentioning SEPNUpdated 7d ago
Every FINWIRES story that references SEPN, newest first.
Septerna (SEPN) has an average rating of buy and mean price target of $45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Septerna (SEPN) said Monday that initial participants have been dosed in a phase 1 clinical study of its experimental oral hypoparathyroidism treatment, SEP-479.The placebo-controlled evaluation will enroll a maximum of 150 healthy adults to assess the safety and physical processing of the medication across single and multiple ascending doses, the company said.The company will also monitor changes in blood calcium levels and other biological markers, with results anticipated in late 2026 or early 2027, it said.Price: $23.40, Change: $+0.31, Percent Change: +1.34%
